Department of Radiology, Oncology and Radiation Science, Uppsala University, Akademiska Sjukhuset, Uppsala, Sweden.
Ups J Med Sci. 2012 May;117(2):225-36. doi: 10.3109/03009734.2012.658974.
In rectal cancer treatment, both the local primary and the regional and systemic tumour cell deposits must be taken care of in order to improve survival. The three main treatments, surgery, radiotherapy, and chemotherapy, each with their own advantages and limitations, must then be combined to improve results. Several large randomized trials have shown that combinations of the modalities have markedly reduced the loco-regional recurrences, but have not yet had any major influence on overall survival. The best integration of the weakest modality, to date the drugs (conventional cytotoxics and biologicals), is not known. A new generation of trials exploring the best sequence of treatments is required. Furthermore, treatment of rectal cancer is administered to populations of individuals, based upon clinical factors and imaging, and can presently not be further individualized. There is an urgent need to develop response predictors.
在直肠癌治疗中,为了提高生存率,必须兼顾局部原发灶和区域及全身肿瘤细胞沉积。然后,必须结合手术、放疗和化疗这三种主要治疗方法,各自具有优势和局限性,以提高疗效。几项大型随机试验表明,这些方法的联合显著降低了局部区域复发率,但尚未对总生存率产生任何重大影响。迄今为止,药物(传统细胞毒性药物和生物制剂)作为最薄弱的治疗方法,其最佳整合方式尚不清楚。需要开展新一代试验来探索最佳的治疗顺序。此外,目前,直肠癌的治疗是根据临床因素和影像学对人群进行的,不能进一步个体化。迫切需要开发反应预测因子。